dc.identifier.uri |
http://dx.doi.org/10.15488/1164 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/1188 |
|
dc.contributor.author |
Mahlich, Jörg
|
|
dc.contributor.author |
Groß, Mona
|
|
dc.contributor.author |
Kuhlmann, Alexander
|
|
dc.contributor.author |
Bogner, Johannes
|
|
dc.contributor.author |
Heiken, Hans
|
|
dc.contributor.author |
Stoll, Matthias
|
|
dc.date.accessioned |
2017-02-24T08:49:28Z |
|
dc.date.available |
2017-02-24T08:49:28Z |
|
dc.date.issued |
2016 |
|
dc.identifier.citation |
Mahlich, J.; Groß, M.; Kuhlmann, Alexander; Bogner, J.; Heiken, H. et al.: The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany. In: Journal of Pharmaceutical Policy and Practice 9 (2016), Nr. 1, 39. DOI: https://doi.org/10.1186/s40545-016-0092-4 |
|
dc.description.abstract |
Background: This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r) -based initial treatment regimen. Methods: The study is based on a sub analysis of a nation-wide multi-centre, non-interventional, prospective cohort study. 133 patients were identified, who received antiretroviral first-line therapy. By means of a logistic regression, factors that determine the treatment strategy for treatment-naïve patients were analysed. Results: Compared to patients receiving a NNRTI-based initial regimen, patients treated with PI/r are slightly younger, less educated, in a later stage of HIV and have more concomitant diseases. Regression analysis revealed that being in a later stage of HIV (CDC-C) is significantly associated with a PI/r-based treatment decision. Conclusions: Our analysis is the first study in Germany investigating sociodemographic and disease-specific parameters associated with a NNRTI- or a PI/r-based initial treatment decision. The results confirm that the treatment decision for a PI/r strategy is associated with disease severity. |
eng |
dc.language.iso |
eng |
|
dc.publisher |
London : BioMed Central Ltd. |
|
dc.relation.ispartofseries |
Journal of Pharmaceutical Policy and Practice 9 (2016), Nr. 1 |
|
dc.rights |
CC BY 4.0 Unported |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
AIDS |
eng |
dc.subject |
Antiretroviral treatment |
eng |
dc.subject |
HIV infection |
eng |
dc.subject |
NNRTI |
eng |
dc.subject |
PI |
eng |
dc.subject |
Treatment decision |
eng |
dc.subject.ddc |
610 | Medizin, Gesundheit
|
ger |
dc.title |
The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany |
eng |
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.issn |
2052-3211 |
|
dc.relation.doi |
https://doi.org/10.1186/s40545-016-0092-4 |
|
dc.bibliographicCitation.issue |
1 |
|
dc.bibliographicCitation.volume |
9 |
|
dc.bibliographicCitation.firstPage |
39 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|